2,271 press releases in English indexed under biotech & pharma.
Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study
NIJMEGEN, The Netherlands – 7 October 2026 – Byondis B.V., a private biopharmaceutical company engineering antibody-drug conjugates (ADCs) to tackle the cancers that current therapies cannot reach, will share progress from its platform technology portfolio at World ADC San Diego, the world's largest ADC conference, being held from 12-15 October in San Diego, USA.
As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS
ANN ARBOR, Mich., Oct. 07, 2026 -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Renata in response to Renata’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Renata has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
SAN FRANCISCO, Oct. 07, 2026 -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company developing novel immune modulators to address the unmet need in immunological and inflammatory diseases, today announced an oral presentation at the United European Gastroenterology (UEG) Week 2026 meeting, taking place October 17–20, 2026, in Barcelona, Spain. The presentation will feature new data from AltruBio’s Phase 2a ASCEND UC2a trial (NCT06109441) evaluating its lead asset, ALTB-268, in patients with moderately to severely active ulcerative colitis with an inadequate response to prior advanced therapy.
WALTHAM, Mass., Oct. 07, 2026 -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.
- Three-phase, 36-month award aims to extend BrainEx perfusion from 24 hours to up to two weeks, enabling longitudinal studies of human brain biology and therapeutic responses -
REDWOOD CITY, Calif., Oct. 07, 2026 -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten public offering on September 18, 2025 (the "Warrants"). The purchase price is $0.324 in cash per Warrant, without interest (the "Offer Purchase Price"). The purpose of the Offer is to reduce the number of shares of Common Stock that would become outstanding upon the exercise of the Warrants, thereby reducing the potential dilutive impact of the Warrants, and providing shareholders and prospective investors greater certainty as to the Company’s capital structure. Warrants tendered in the Offer will be retired and cancelled.
Boulder, CO Wednesday Oct 7, 2026 @ 7:00 AM Eastern — C60 Power, a woman owned wellness company specializing in Carbon 60 products for people and animals, celebrates National C60 Day every October 9. Created by C60 Power, the observance falls on the anniversary of October 9, 1996, the day the Royal Swedish Academy of Sciences announced the Nobel Prize in Chemistry for the discovery of fullerenes. This year, consumers can enjoy educational events, community stories, and a 20% storewide sale at ShopC60.com. National C60 Day, also known as National Carbon 60 Day, C60 Day or Carbon 60 Day, recognizes the discovery of C60, also called buckminsterfullerene or a "buckyball." C60 is a hollow, spherical molecule made of exactly 60 carbon atoms arranged in 12 pentagons and 20 hexagons, the same pattern found on a classic soccer ball. A Discovery Written in the Stars In 1985, British chemist Harold Kroto joined Rice University scientists Robert Curl and Richard Smalley to recreate the chemistry of carbon rich stars in the laboratory, and their experiments revealed C60. Kroto, a longtime admirer of architect R. Buckminster Fuller's geodesic domes helped give the molecule its name in honor of Buckminster. In 1990, Wolfgang Krätschmer and Donald Huffman developed a method to produce C60 in quantities large enough to study, and the journal Science named buckminsterfullerene its Molecule of the Year for 1991. Curl, Kroto, and Smalley were awarded the 1996 Nobel Prize in Chemistry for their discovery. In 2010, astronomers using NASA's Spitzer Space Telescope detected C60 in Tc 1, a cloud of gas and dust shed by a dying star, the first confirmed sighting of buckyballs in space. "National C60 Day gives us an opportunity to honor the science that introduced this extraordinary molecule to the world. This holiday may help consumers understand the importance of purity, and 3rd-party testing, along with the opportunity to learn more about the potential of the molecule," said Jessica MacNaughton, CEO and cofounder of C60 Power. "Our goal is to make reliable C60 education more accessible and give people the information they need to make informed choices for themselves and their animals." What Researchers Are Studying Since its discovery, C60 research has expanded into chemistry, materials science, nanotechnology, energy, skincare and wellness. Its ability to interact with free radicals is one reason C60 continues to attract attention in antioxidant research. Interest in C60 and healthy aging grew after a 2012 study reported that rats given C60 dissolved in olive oil lived longer than untreated rats. Consumers can review published studies at WhatIsC60.org and ShopC60.com/research. How to Celebrate National C60 Day Share the story. Post a buckyball sketch, a molecule model or the most surprising fact you learned, tag @C60Power and use #NationalC60Day, #Carbon60 and #C60. Explore the research. Start by with reviewing the research at WhatIsC60.org, or ShopC60.com/research and share one study or question on social media with #NationalC60Day. Take the C60 Challenge. Purchase C60 at ShopC60.com on October 9th and then download the C60 30-Day Challenge Journal to track your C60 routine and how you feel. https://shopc60.com/wp-content/uploads/2025/07/c60-journal.pdf Deals and Offers National C60 Day Sale: Save 20% storewide on C60 Power products, from C60 oils and gummies to skincare and C60 for pets. This code is valid until October 9, 2026 only at ShopC60.com.Use code CELEBRATE20 at checkout on ShopC60.com. Ready to try C60 after National C60 Day? Visit ShopC60.com and use code NATIONAL10 for 10 percent off your first order. About C60 Power C60 Power is an American woman owned wellness company,originally founded in 2016 as C60 Purple Power. The company specializes in the manufacturing of health and wellness products containing Carbon 60 including C60 oils, gummies, skincare, and specialty formulations for pets; , all made with 99.99 percent pure, sublimated C60, and certified organic carrier oils. All C60 Power products are third-party tested for safety, quality, purity, and bioavailability. Where to Buy C60 Power products are available at ShopC60.com, TrulyFree.com and Amazon.com, through many healthcare providers, and at select health and wellness retailers across the United States. Media Contact Lindsay O'Neill-O'Keefe Wellness Eternal Email Contact 914-846-9444 Disclaimer: These statements have not been evaluated by the Food and Drug Administration. C60 Power products are not intended to diagnose, treat, cure, mitigate or prevent any disease. Individual results may vary.
Zurich, Switzerland, October 7, 2026 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive 12-month interim results from the Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269), demonstrating durable, sustained and clinically relevant bladder health benefits in patients treated with its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy for female stress urinary incontinence (SUI). SUI represents a high unmet medical need, affecting more than 150 million women worldwide, for which no approved therapy presently addresses the underlying cause. The study results were presented in an oral session at the Annual Meeting of the International Continence Society (ICS) in Maastricht, the Netherlands, on October 7, 2026 [1].
Garching / Munich, October 7, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that new data for 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) will be unveiled in two top-rated oral presentations at the European Association of Nuclear Medicine (EANM) Congress, held from October 17 – 21, 2026 in Vienna, Austria. Anthime Flaus, MD, PhD, of the Hospital Louis Pradel in Bron, France will present dose-response findings from the Phase 3 COMPETE trial, in which patients with gastroenteropancreatic neuroendocrine tumors were treated with 177Lu-edotreotide. Alina Küper, MD, of the University Hospital Essen in Germany will present interim results from an independent, retrospective analysis of the PET/CT imaging agent Ga-DPI-4452 (CA-IX peptide) used for the imaging of clear cell renal cell carcinoma in a bicenter registry. In addition to the scientific presentations, ITM will host a booth reception and separate Meet the Expert session. At this session, Dr. Neil Quigley will share insights into the production of Actinium-225 (225Ac) using medium-energy cyclotrons and present Actineer’s approach to increase production capacity. Actineer is the joint venture between ITM and Canadian Nuclear Laboratories. Oral Presentation Details Title: Ga-DPI-4452 (CA-IX peptide) PET/CT for Imaging Clear Cell Renal Cell Carcinoma: Interim Results from a Bicentre Registry Session Title: Renal Cell Cancer and Novel Targets Session Number: 506 Track: Clinical Oncology Date and Time: Sunday, October 18, 2026, 15:00 – 16:30 CEST Location: Hall C Presenter: Dr. Alina Küper, University Hospital Essen, Essen, Germany Title: Dose-response Analysis in Patients with Gastroenteropancreatic Neuroendocrine Tumors Receiving [¹⁷⁷Lu]Lu-edotreotide Session Title: From Clinical Dosimetry to Treatment Adaptation in [¹⁷⁷Lu] Therapy Session Number: 1505 Track: Cutting Edge Science Date and Time: Tuesday, October 20, 2026, 15:00 – 16:30 CEST Location: Hall B Presenter: Dr. Anthime Flaus, Hospital Louis Pradel, Bron, France Meet the Expert Session Title: 225Ac Production via Medium-Energy Cyclotrons: Actineer’s Path Towards Increasing Production Capacities Date and Time: Monday, October 19, 2026, 10:30 – 10:50 CEST Location: ITM Booth #415, Hall X4 Presenter: Dr. Neil Quigley, Radioisotope Scientific Expert at ITM Conference attendees will have the opportunity to learn more about ITM and Lumara Bio, a division of ITM, by visiting the company booth, #415 in Hall X4. Attendees are also invited to join the ITM team for an informal booth reception and networking opportunity on Monday, October 19, from 16:00 to 17:00 CEST. 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) are investigational products and are not approved by any regulatory authority for the safety and/or efficacy of any intended use. About the COMPETE Trial The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs. About Ga-DPI-4452 (ITM-94) Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, CA-IX peptide, or ITM-94) is an investigational gallium-68-radiolabeled PET imaging agent targeting carbonic anhydrase IX (CAIX), a cell surface protein that plays a key role in tumor growth, invasion, and metastasis. ITM-94 is designed to non-invasively improve the characterization of indeterminate renal masses and enable more accurate diagnosis and disease staging of clear cell renal cell carcinoma (ccRCC). ITM-94 received Fast Track Designation from the FDA in October 2025. [68Ga]Ga-DPI-4452 is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com About Lumara Bio Lumara Bio, a division of ITM, builds on more than two decades of radiopharmaceutical expertise and is advancing a focused pipeline of targeted therapies for cancers where treatment options remain limited. https://lumarabio.com ITM Contact Corporate Communications Kathleen Noonan/Julia Westermeir Phone: +49 89 329 8986 1500 Email: communications@itm-radiopharma.com Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: investors@itm-radiopharma.com